Market
Regulatory outcome for orforglipron by end of 2026
2
Resolution / Starting Odds
Approved • 25%
Rejected • 25%
Approval delayed • 25%
Other outcome • 25%
FDA and other regulatory body announcements
Story
Eli Lilly Anticipates Approval for Orforglipron Weight-Loss Pill in Early 2026
Jan 13, 2025, 06:07 PM
Eli Lilly & Co. is anticipating regulatory approval for its experimental weight-loss pill, orforglipron, as early as early 2026, according to CEO Dave Ricks. Ricks, speaking at the JPMorgan Healthcare Conference in San Francisco, indicated that data on the pill is expected by mid-2025. He highlighted that the oral form of the drug would be more convenient for patients and easier to manufacture at a large scale compared to the company's current injectable weight-loss drugs, which have faced supply shortages due to production constraints.
View original story
Similar markets
FDA only • 25%
Both FDA and EMA • 25%
EMA only • 25%
Neither • 25%
Approved • 33%
Rejected • 33%
Request for more data • 34%
Phase 2 trial completion • 25%
No significant milestone • 25%
Regulatory approval in any region • 25%
Phase 3 trial initiation • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
No • 50%
Yes • 50%
None • 25%
China • 25%
European Union • 25%
United States • 25%
Request for more data • 25%
Approved • 25%
Other outcome • 25%
Rejected • 25%
Approve continuation • 25%
Request modifications • 25%
Suspend trial • 25%
No action taken • 25%
Approved • 25%
Approved with conditions • 25%
Rejected • 25%
Decision delayed • 25%